Black Rock Inc. Compass Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 6,613,637 shares of CMPX stock, worth $10.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,613,637

Previous 6,032,466 9.63%

Holding current value

$10.5 Million

Previous $11.9 Million 44.63%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.0 - $1.85 $581,171 - $1.08 Million	581,171 Added 9.63%	6,613,637 $6.61 Million
Q1 2024 May 10, 2024	SELL	$1.2 - $2.29 $227,811 - $434,740	-189,843 Reduced 3.05%	6,032,466 $11.9 Million
Q4 2023 Feb 13, 2024	BUY	$1.4 - $1.98 $348,003 - $492,176	248,574 Added 4.16%	6,222,309 $9.71 Million
Q3 2023 Nov 13, 2023	SELL	$1.87 - $3.25 $109,501 - $190,310	-58,557 Reduced 0.97%	5,973,735 $11.8 Million
Q2 2023 Aug 11, 2023	BUY	$2.64 - $3.48 $11.9 Million - $15.6 Million	4,491,397 Added 291.48%	6,032,292 $19.2 Million
Q1 2023 May 12, 2023	BUY	$3.14 - $5.48 $951,777 - $1.66 Million	303,114 Added 24.49%	1,540,895 $5.04 Million
Q4 2022 Feb 13, 2023	BUY	$2.55 - $5.41 $931,474 - $1.98 Million	365,284 Added 41.87%	1,237,781 $6.23 Million
Q3 2022 Nov 14, 2022	BUY	$1.9 - $3.37 $1.35 Million - $2.39 Million	709,071 Added 433.88%	872,497 $1.99 Million
Q2 2022 Aug 12, 2022	BUY	$1.43 - $3.1 $233,699 - $506,620	163,426 New	163,426 $433,000

Others Institutions Holding CMPX

# of Institutions

Shares Held

92M

Call Options Held

Put Options Held

View Full List

About Compass Therapeutics, Inc.

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $161M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

More about CMPX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account